SAN DIEGO, April 11, 2023 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced its continued participation at various global conferences throughout April and May.

"Our participation in spine conferences around the world reflects our belief in partnering with the most influential societies, study groups and congresses to advance spine care and change patient lives," said Chris Barry, chief executive officer at NuVasive. "We look forward to showcasing our comprehensive, procedurally integrated portfolios, our commitment to more intelligent surgery with the Pulse platform, and the continued celebration of 20 years of XLIF."

Learn about NuVasive's comprehensive 360 portfolios—X360, C360, P360 and Complex—enabled by the Pulse platform. Procedural focuses at each conference include:

• 52^nd Annual Meeting of the Japanese Society for Spinal Surgery and Related Research (JSSR): April 13–15 in Sapporo, Japan, NuVasive will celebrate XLIF and showcase the X360 portfolio.
• BritSpine 2023: April 18–20 in Scotland, United Kingdom, NuVasive will feature the X360 and Complex portfolios enabled by Pulse at booth #1.
• 2023 American Association of Neurological Surgeons (AANS) Annual Scientific Meeting: April 21–23 in Los Angeles, NuVasive will celebrate XLIF, feature all 360 portfolios and highlight the Spine Precision Partnership with Siemens Healthineers at booth #1147.
• 2023 Pediatric Orthopaedic Society of North America (POSNA) Annual Meeting: April 26–28 in Nashville, NuVasive will feature its magnetically adjustable implant systems, Precice and MAGEC at booth #603/703.
• SpineWeek 2023: May 1–5 in Melbourne, Australia, NuVasive will celebrate XLIF and feature X360, C360 and Complex portfolios enabled by Pulse at booth #C2.

<sup>About NuVasive

NuVasive, Inc. (NASDAQ: NUVA) is the leader in spine technology innovation, with a mission to transform surgery, advance care, and change lives. The Company's less-invasive, procedurally integrated surgical solutions are designed to deliver reproducible and clinically proven outcomes. The Company's comprehensive procedural portfolio includes surgical access instruments, spinal implants, fixation systems, biologics, software for surgical planning, navigation and imaging solutions, magnetically adjustable implant systems for spine and orthopedics, and intraoperative neuromonitoring technology and service offerings. With more than $1 billion in net sales, NuVasive operates in more than 50 countries serving surgeons, hospitals, and patients. For more information, please visit www.nuvasive.com.</sup>

^{Forward-Looking Statements
NuVasive cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, risks associated with acceptance of the Company's surgical products and procedures by spine surgeons and hospitals, development and acceptance of new products or product enhancements, clinical and statistical verification of the benefits achieved via the use of NuVasive's products, the Company's ability to adequately manage inventory as it continues to release new products, its ability to recruit and retain management and key personnel, and the other risks and uncertainties described in NuVasive's news releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.}

View original content to download multimedia:https://www.prnewswire.com/news-releases/nuvasive-to-participate-in-upcoming-global-spine-conferences-301793872.html

SOURCE NuVasive, Inc.

Investor, Juliet C. Cunningham, NuVasive, Inc., 858-210-2129, [email protected]; Media: Melanie Ordoñez, NuVasive, Inc., 858-722-3899, [email protected]

SAN DIEGO, March 20, 2023 /PRNewswire/ - NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the use of its Precice all-internal limb lengthening solution to include pediatric patients*. The expanded clearance extends the clinical benefits of Precice to a wider range of patients.

"Everyone faced with limb length discrepancy (LLD), especially pediatric patients, should have access to a non-invasive limb lengthening solution," said Pete Ligotti, leader of NuVasive Specialized Orthopedics (NSO). "Backed by more than 100 peer-reviewed studies, the difference with Precice is that it accommodates the changing clinical needs of patients as they heal, grow, and age, reducing the need for further surgeries¹ throughout treatment."

Precice is a magnetically adjustable technology that utilizes an external remote to non-invasively lengthen implants. The Precice nail has been implanted more than 15,000 times, by more than 2,000 surgeons, and in nearly 50 countries. As a division of NuVasive, NSO is focused on the design and innovation of disruptive orthopedic solutions for complex orthopedic reconstruction and limb lengthening.

"Precice has over a decade's worth of clinical data and has truly changed the standard of care for my patients," said Dr. John Herzenberg, director of pediatric orthopedics at Sinai Hospital. "This new indication is significant for my practice as the majority of my patients are under the age of 18, and it provides me with the assurance I need to offer Precice as a pediatric LLD solution."

Furthering the Company's ability to treat the full continuum of care, the next phase of NSO's orthopedic innovation is intelligent surgery. The Company's asset acquisition efforts in December 2022 position NSO as an early player in next-generation motorized technology for dynamic orthopedic implants.

^{*The Precice IMLL System is indicated for limb lengthening of the femur and tibia in pediatric patients (greater than 12 years old).}

^{1. Richardson, S, Schairer W, Fragomen A, et al. Cost Comparison of Femoral Distraction Osteogenesis With External Lengthening Over a Nail Versus Internal Magnetic Lengthening Nail. J Am Acad Orthop Surg 2019 May 1;27(9):e430-36.}

^{About NuVasive
NuVasive, Inc. (NASDAQ: NUVA) is the leader in spine technology innovation, with a mission to transform surgery, advance care, and change lives. The Company's less-invasive, procedurally integrated surgical solutions are designed to deliver reproducible and clinically proven outcomes. The Company's comprehensive procedural portfolio includes surgical access instruments, spinal implants, fixation systems, biologics, software for surgical planning, navigation and imaging solutions, magnetically adjustable implant systems for spine and orthopedics, and intraoperative neuromonitoring technology and service offerings. With more than $1 billion in net sales, NuVasive operates in more than 50 countries serving surgeons, hospitals, and patients. For more information, please visit www.nuvasive.com.}

^{Forward-Looking Statements
NuVasive cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, risks associated with acceptance of the Company's surgical products and procedures by spine surgeons and hospitals, development and acceptance of new products or product enhancements, clinical and statistical verification of the benefits achieved via the use of NuVasive's products, the Company's ability to adequately manage inventory as it continues to release new products, its ability to recruit and retain management and key personnel, and the other risks and uncertainties described in NuVasive's news releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.}

View original content to download multimedia:https://www.prnewswire.com/news-releases/nuvasive-specialized-orthopedics-expands-indications-of-precice-limb-lengthening-system-to-treat-pediatric-patients-301775389.html

SOURCE NuVasive, Inc.

Investor contact: Juliet C. Cunningham, NuVasive, Inc., 858-210-2129, [email protected]; Media contact: Melanie Ordoñez, NuVasive, Inc., 858-722-3899, [email protected]

SAN DIEGO, March 13, 2023 /PRNewswire/ - NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today the 20-year milestone achievement of its lateral lumbar procedure, extreme lateral interbody fusion (XLIF).

"20 years ago, we set out to make spine surgery more reproducible and improve patient outcomes through the development and introduction of the XLIF procedure," said Ryan Donahoe, chief technology officer at NuVasive. "Through our leadership in outcome-driven design, partnership with the best spine clinicians around the globe, and a continued focus on clinical education and validation, we have learned that it is foundational to approach innovation across the full continuum of spine care."

"It's been quite a journey since I started working with NuVasive in 2001, being attracted to the vision of making spine surgery better. In collaboration with a handful of my peers and the NuVasive team, creating the XLIF procedure was a decision that stemmed from us realizing that the outcomes we were seeing weren't good enough," said Dr. Frank Phillips, director of the division of spine surgery at Rush University Medical Center. "This proven innovation is an incredible example of how thoughtful procedural design and reliable, reproducible clinical results can improve the overall care experience."

Today, with ~300,000 procedures performed, 200+ educational courses hosted, 500+ peer-reviewed publications and 60+ products launched, XLIF continues to demonstrate superior and more predictable outcomes than traditional spinal fusion procedures.^1-4 Specifically designed to treat pathologies effectively and reproducibly at levels L4-L5 and above, XLIF has been proven to reduce operative time, incision size, blood loss during surgery, length of hospital stay, postoperative pain, and postoperative recovery time.^1-4

"Over the years, I've seen XLIF take over the lateral market, making less-invasive spine surgery more reproducible," said Dr. Paul Holman, chief of spinal neurosurgery at Houston Methodist. "When paired with the enabling technologies within Pulse, XLIF unlocks even more clinical value for both the surgeon and the patient."

Building on the legacy of XLIF, the Company has since launched its X360, P360, C360 and Complex procedural portfolios. The next phase of NuVasive innovation is intelligent surgery. From planning to execution to postoperative data, intelligent surgery will proliferate each portfolio to provide better patient, surgeon and hospital outcomes.

"The concept of intelligent surgery will take what we know of XLIF and more recently with X360, to greater heights," said Alex Thomas, neurosurgeon at Atlantic Brain and Spine. "I'm excited to see how we can leverage the power of data to make better decisions preoperatively and intraoperatively, and then track our outcomes more intelligently, postoperatively."

<sup>1. Sembrano JN, Tohmeh A, Isaacs R, et al. Two-year comparative outcomes of MIS lateral and MIS transforaminal interbody fusion in the treatment of degenerative spondylolisthesis: part I: clinical findings. Spine 2016;41(Suppl 8):S123-32.
2. Lehmen JA, Gerber EJ. MIS lateral spine surgery: A systematic literature review of complications, outcomes, and economics. Eur Spine J 2015;24(Suppl 3):287-313.
3. Rihn JA, Patel R, Makda J, et al. Complications associated with single-level transforaminal lumbar interbody fusion. Spine J 2009;9(8):623-9.
4. Lucio JC, VanConia RB, Deluzio KJ, et al. Economics of less invasive spinal surgery: an analysis of hospital cost differences between open and minimally invasive instrumented spinal fusion procedures during the perioperative period. Risk Management and Healthcare Policy 2012;5:65-74.</sup>

^{About NuVasive
NuVasive, Inc. (NASDAQ: NUVA) is the leader in spine technology innovation, with a mission to transform surgery, advance care, and change lives. The Company's less-invasive, procedurally integrated surgical solutions are designed to deliver reproducible and clinically proven outcomes. The Company's comprehensive procedural portfolio includes surgical access instruments, spinal implants, fixation systems, biologics, software for surgical planning, navigation and imaging solutions, magnetically adjustable implant systems for spine and orthopedics, and intraoperative neuromonitoring technology and service offerings. With more than $1 billion in net sales, NuVasive operates in more than 50 countries serving surgeons, hospitals, and patients. For more information, please visit www.nuvasive.com.}

^{Forward-Looking Statements
NuVasive cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, risks associated with acceptance of the Company's surgical products and procedures by spine surgeons and hospitals, development and acceptance of new products or product enhancements, clinical and statistical verification of the benefits achieved via the use of NuVasive's products, the Company's ability to adequately manage inventory as it continues to release new products, its ability to recruit and retain management and key personnel, and the other risks and uncertainties described in NuVasive's news releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.}

View original content to download multimedia:https://www.prnewswire.com/news-releases/nuvasive-celebrates-20-year-milestone-of-the-xlif-procedure-301769454.html

SOURCE NuVasive, Inc.

Investor contact: Juliet C. Cunningham, NuVasive, Inc., 858-210-2129, [email protected]; Media contact: Melanie Ordoñez, NuVasive, Inc., 858-722-3899, [email protected]

SAN DIEGO, Feb. 21, 2023 /PRNewswire/ - NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the use of its Modulus Cervical interbody implant with a bone void filler, further enhancing the Company's C360 portfolio. The expanded indications deliver new value in the cervical segment to surgeons and hospitals.

"We believe that delivering differentiated procedural solutions that are clinically and economically advantageous is of paramount importance," said Ryan Donahoe, chief technology officer at NuVasive. "This clearance represents a significant milestone towards that goal, expanding our advanced materials combination of Modulus and Attrax Putty to our cervical interbody within the C360 portfolio."

Attrax Putty is the first synthetic bone graft substitute to receive FDA cleared Indications for Use in thoracolumbar interbody fusion spacers in December 2021. Subsequently published evidence clinically validated the combination of NuVasive's Advanced Materials Science solutions, Modulus XLIF and Attrax Putty, as having clinical and economic advantages over traditional, non-porous interbody implants and premium-priced biologics.¹

"When planning my interbody fusion cases, knowing that both the implant and the biological environment are participating in fusion gives me confidence for the longer constructs I usually perform in my practice," said Chris Shaffrey, Duke Health University.

^{1. Malone H, Mundis GM, Collier M, et al. A novel approach to evaluating lateral lumbar interbody fusion using a 3D-Printed Porous Titanium Interbody Device. 27th International Meeting on Advanced Spine Techniques. Online. July-August 2020.}

^{About NuVasive
NuVasive, Inc. (NASDAQ: NUVA) is the leader in spine technology innovation, with a mission to transform surgery, advance care, and change lives. The Company's less-invasive, procedurally integrated surgical solutions are designed to deliver reproducible and clinically proven outcomes. The Company's comprehensive procedural portfolio includes surgical access instruments, spinal implants, fixation systems, biologics, software for surgical planning, navigation and imaging solutions, magnetically adjustable implant systems for spine and orthopedics, and intraoperative neuromonitoring technology and service offerings. With more than $1 billion in net sales, NuVasive operates in more than 50 countries serving surgeons, hospitals, and patients. For more information, please visit www.nuvasive.com.}

^{Forward-Looking Statements
NuVasive cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, risks associated with acceptance of the Company's surgical products and procedures by spine surgeons and hospitals, development and acceptance of new products or product enhancements, clinical and statistical verification of the benefits achieved via the use of NuVasive's products, the Company's ability to adequately manage inventory as it continues to release new products, its ability to recruit and retain management and key personnel, and the other risks and uncertainties described in NuVasive's news releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.}

 View original content to download multimedia:https://www.prnewswire.com/news-releases/nuvasive-enhances-c360-portfolio-with-expanded-indications-for-modulus-cervical-and-attrax-putty-301751258.html

SOURCE NuVasive, Inc.

Investor: Juliet C. Cunningham, NuVasive, Inc., 858-210-2129, [email protected]; Media: Melanie Ordoñez, NuVasive, Inc., 858-722-3899, [email protected]